{"id":70781,"date":"2026-05-12T11:03:24","date_gmt":"2026-05-12T11:03:24","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70781"},"modified":"2026-10-15T10:33:57","modified_gmt":"2026-10-15T10:33:57","slug":"hgh-fragment-176-191","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ja\/product\/hgh-fragment-176-191\/","title":{"rendered":"HGH\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8176-191"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">\u30af\u30a4\u30c3\u30af\u30a2\u30f3\u30b5\u30fc \u2014 HGH Fragment 176-191\u3068\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h3>\n<p style=\"margin: 0;\"><strong>HGH\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8176-191<\/strong> \u306f\u3001\u30d2\u30c8\u6210\u9577\u30db\u30eb\u30e2\u30f3\u306eC\u672b\u7aef\u6b8b\u57fa176\uff5e191\u306b\u76f8\u5f53\u3059\u308b16\u30a2\u30df\u30ce\u9178\u306e\u5408\u6210\u30da\u30d7\u30c1\u30c9\u3067\u3042\u308a\u3001 <a href=\"https:\/\/medsbase.com\/ja\/hgh-191aa\/\">\u30d2\u30c8\u6210\u9577\u30db\u30eb\u30e2\u30f3<\/a>. In published studies it retains the lipolytic (fat-mobilising) and glucose-modulating activity of the parent HGH molecule but lacks GH-receptor binding affinity and therefore does not activate IGF-1 production, chondrocyte signalling, or any of the growth-promoting effects of full-length HGH. Sequence: YLRIVQCRSVEGSCGF. Supplied in 5\u201315\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>MedsBase\u3067\u5f97\u3089\u308c\u308b\u3082\u306e\uff1a<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/ja\/reviews\/\">\u30ab\u30b9\u30bf\u30de\u30fc\u30ec\u30d3\u30e5\u30fc<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 \u3059\u3079\u3066\u306e\u3054\u6ce8\u6587\u306f\u3001\u5f53\u5e97\u306e <a href=\"https:\/\/medsbase.com\/ja\/medsbase-re-shipment-assurance-policy\/\"><strong>\u518d\u767a\u9001\u4fdd\u8a3c\u30dd\u30ea\u30b7\u30fc<\/strong><\/a> \u2014 \u4e07\u304c\u4e00\u300120\u55b6\u696d\u65e5\u4ee5\u5185\u306b\u5546\u54c1\u304c\u5c4a\u304b\u306a\u3044\u5834\u5408\u306f\u3001\u518d\u767a\u9001\u3044\u305f\u3057\u307e\u3059\u3002<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">\u4ed5\u69d8<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">\u8a73\u7d30<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>CAS\u756a\u53f7<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">66004-57-7\uff08HGH Fragment 176-191; AOD9604 CAS 221231-10-9\u3068\u306f\u7570\u306a\u308b\uff09<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5206\u5b50\u5f0f<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>78<\/sub>H<sub>125<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5206\u5b50\u91cf<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1817.06 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u914d\u5217<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe\uff08YLRIVQCRSVEGSCGF\u300116\u30a2\u30df\u30ce\u9178\uff1b\u5929\u7136\u30d2\u30c8\u6210\u9577\u30db\u30eb\u30e2\u30f3\u306e176\uff5e191\u4f4d\u306b\u76f8\u5f53\u3057\u3001\u89aa\u5206\u5b50\u306eCys182\u2013Cys189\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u7d50\u5408\u3092\u4fdd\u6301\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5f62\u614b<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u51cd\u7d50\u4e7e\u71e5\u7c89\u672b\uff08\u767d\u8272\u301c\u5fae\u9ec4\u8272\uff09<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u7d14\u5ea6<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599%\uff08HPLC\u691c\u8a3c\u6e08\u307f\u3001COA\u306f\u3054\u8981\u671b\u306b\u5fdc\u3058\u3066\u63d0\u4f9b\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u4fdd\u7ba1\u65b9\u6cd5<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u51cd\u7d50\u4e7e\u71e5\u54c1\uff1a\u4f7f\u7528\u6642\u5728\u5eab\u306f2\uff5e8\u2103\uff08\u51b7\u8535\uff09\u306b\u4fdd\u7ba1\u3002\u672a\u958b\u5c01\u30d0\u30a4\u30a2\u30eb\u306e\u9577\u671f\u4fdd\u7ba1\u306b\u306f\u221220\u2103\u3002\u518d\u6eb6\u89e3\u5f8c\uff1a2\uff5e8\u2103\u3067\u7d0430\u65e5\u4ee5\u5185\u306b\u4f7f\u7528\u3002\u5149\u304b\u3089\u4fdd\u8b77\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u518d\u6eb6\u89e3\u6db2\u306e\u51cd\u7d50\u878d\u89e3\u306f\u907f\u3051\u3066\u304f\u3060\u3055\u3044\u3002<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u6eb6\u89e3\u6027<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u9759\u83cc\u6c34\uff08\u63a8\u5968\uff09\u307e\u305f\u306f\u77ed\u6642\u9593\u4f7f\u7528\u306e\u5834\u5408\u306f\u6ec5\u83cc\u6c34<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>HGH Fragment 176-191\u3068\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h2>\n<p><strong>HGH\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8176-191<\/strong> is a 16-amino-acid synthetic peptide corresponding to the C-terminal residues 176 through 191 of native human growth hormone. The fragment was identified through structure-function studies on HGH conducted at Monash University in the 1990s, when investigators systematically truncated and modified the HGH molecule to map the regions responsible for each of its multiple biological activities. The 176-191 region proved to retain the lipolytic (fat-mobilising) and antilipogenic activity of full-length HGH while completely losing the GH-receptor-binding domain that resides in the N-terminal portion of the parent molecule. The well-characterised sequence is YLRIVQCRSVEGSCGF with the native Cys182\u2013Cys189 intramolecular disulfide bridge preserved (these become Cys7\u2013Cys14 within the fragment numbering). Molecular weight 1817.06\u00a0Da, empirical formula C<sub>78<\/sub>H<sub>125<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub>. AOD9604\u3068\u306f\u7570\u306a\u308a\u307e\u3059\u3002 <strong>AOD9604\u3068\u306f\u7570\u306a\u308b<\/strong> \u2014 an analog developed by Metabolic Pharmaceuticals that adds an N-terminal tyrosine substitution (creating Tyr-HGH 177-191) and modifies the disulfide bridge. AOD9604 has its own CAS (221231-10-9) and pharmacological profile and should not be confused with the unmodified 176-191 fragment supplied here. HGH Fragment 176-191 is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. The fragment is <strong>\u627f\u8a8d\u3055\u308c\u3066\u3044\u307e\u305b\u3093<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. For the full-length parent molecule, see our <a href=\"https:\/\/medsbase.com\/ja\/hgh-191aa\/\">HGH 191AA<\/a> \u88fd\u54c1\u30da\u30fc\u30b8\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002 <\/p>\n<h2>\u4f5c\u7528\u6a5f\u5e8f \u2014 GH\u53d7\u5bb9\u4f53\u7d50\u5408\u3092\u4f34\u308f\u306a\u3044\u8102\u80aa\u5206\u89e3\u6d3b\u6027<\/h2>\n<p>HGH Fragment 176-191\u304c\u4f5c\u7528\u6a5f\u5e8f\u7684\u306b\u969b\u7acb\u3063\u3066\u3044\u308b\u306e\u306f\u3001 <strong>\u8102\u80aa\u5206\u89e3\u3068\u6210\u9577\u8ef8\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\u306e\u5206\u96e2<\/strong> \u2014 one of the cleanest examples of structure-function dissection in peptide pharmacology studies:<\/p>\n<ul>\n<li><strong>GH\u53d7\u5bb9\u4f53\u7d50\u5408\u306e\u6b20\u5982<\/strong> \u2014 \u5929\u7136\u578bHGH\u306eGH\u53d7\u5bb9\u4f53\u7d50\u5408\u8868\u9762\u306f\u3001\u5206\u5b50\u306eN\u672b\u7aef\u90e8\u5206\uff08\u6b8b\u57fa1\uff5e120\u9818\u57df\uff09\u306b\u542b\u307e\u308c\u3066\u304a\u308a\u3001176\uff5e191\u306eC\u672b\u7aef\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8\u306b\u306f\u542b\u307e\u308c\u3066\u3044\u307e\u305b\u3093\u3002\u305d\u306e\u7d50\u679c\u3001HGH Fragment 176-191\u306f\u6210\u9577\u30db\u30eb\u30e2\u30f3\u53d7\u5bb9\u4f53\uff08GHR\uff09\u306b\u7d50\u5408\u305b\u305a\u3001JAK2\/STAT5\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\u3092\u6d3b\u6027\u5316\u305b\u305a\u3001\u809d\u81d3\u3067\u306eIGF-1\u7523\u751f\u3092\u8a98\u5c0e\u305b\u305a\u3001\u305d\u3057\u3066\u89aa\u5206\u5b50\u306e\u6210\u9577\u4fc3\u9032\u3001\u8edf\u9aa8\u7d30\u80de\u523a\u6fc0\u3001\u307e\u305f\u306f\u30a4\u30f3\u30b9\u30ea\u30f3\u62ee\u6297\u4f5c\u7528\u306e\u3044\u305a\u308c\u3082\u5f15\u304d\u8d77\u3053\u3057\u307e\u305b\u3093\u3002\u89aa <a href=\"https:\/\/medsbase.com\/ja\/hgh-191aa\/\">HGH 191AA<\/a> molecule. This is the defining negative pharmacological property and the basis for its studies utility as a lipolysis-axis-isolating tool.<\/li>\n<li><strong>\u4fdd\u6301\u3055\u308c\u305f\u8102\u80aa\u5206\u89e3\u6d3b\u6027<\/strong> \u2014 Published studies has documented that HGH Fragment 176-191 retains the fat-mobilising activity of full HGH at adipocytes. The exact molecular target underlying the lipolytic effect remains an active studies question; proposed mechanisms include direct action on adipocyte beta-3 adrenergic receptors, modulation of hormone-sensitive lipase, and altered fatty-acid oxidation kinetics. The lipolytic signal is preferentially observed in visceral adipose tissue depots in some published rodent studies, paralleling but mechanistically distinct from the <a href=\"https:\/\/medsbase.com\/ja\/tesamorelin\/\">Tesamorelin<\/a> visceral-adiposity signal.<\/li>\n<li><strong>\u6297\u8102\u80aa\u751f\u6210\u6d3b\u6027<\/strong> \u2014 In addition to stimulating fat mobilisation, HGH Fragment 176-191 suppresses lipogenic gene expression in adipocyte study models \u2014 reducing the rate of new fat storage in parallel with increasing fat mobilisation. The two effects produce a net negative-fat-balance signal in adipose tissue.<\/li>\n<\/ul>\n<p>The structure-function-decoupling property is the principal scientific reason HGH Fragment 176-191 has remained in active studies despite never reaching regulatory approval as a stand-alone therapeutic. It is a useful tool for users who want to study HGH&#8217;s lipolytic effects independently from its growth-promoting effects \u2014 a separation that is impossible to achieve with full-length HGH or with GH secretagogues that drive endogenous full-length GH release. Plasma half-life is short (~30 minutes); subcutaneous administration is the standard administration route. <\/p>\n<h2>Published Evidence<\/h2>\n<p>HGH Fragment 176-191 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>\u8102\u80aa\u7d30\u80de\u306e\u8102\u80aa\u5206\u89e3\u85ac\u7406\u5b66<\/strong> \u2014 \u5358\u96e2\u3055\u308c\u305f\u8102\u80aa\u5206\u89e3\u30e1\u30ab\u30cb\u30ba\u30e0\u306e\u7279\u6027\u8a55\u4fa1\u3001\u30d9\u30fc\u30bf3\u30a2\u30c9\u30ec\u30ca\u30ea\u30f3\u53d7\u5bb9\u4f53\u76f8\u4e92\u4f5c\u7528\u7814\u7a76\u3001\u30db\u30eb\u30e2\u30f3\u611f\u53d7\u6027\u30ea\u30d1\u30fc\u30bc\u6d3b\u6027\u5316\u3001\u8102\u80aa\u9178\u52d5\u54e1\u52d5\u614b<\/li>\n<li><strong>Obesity and body-composition studies<\/strong> \u2014 preclinical DIO rodent models, body-composition (DEXA\/MRI), regional adipose-tissue depot effects (visceral vs subcutaneous), lipolysis-without-growth-axis-confound studies designs<\/li>\n<li><strong>HGH structure-function studies<\/strong> \u2014 \u5929\u7136HGH\u5185\u306e\u6210\u9577\u4fc3\u9032\u30c9\u30e1\u30a4\u30f3\u3068\u8102\u80aa\u5206\u89e3\u6d3b\u6027\u30c9\u30e1\u30a4\u30f3\u306e\u6a5f\u69cb\u7684\u89e3\u660e\uff1bHGH Fragment 176-191\u3092\u6a19\u6e96\u7684\u306a\u300c\u8102\u80aa\u5206\u89e3\u306e\u307f\u300d\u306e\u30c4\u30fc\u30eb\u3068\u3057\u3001 <a href=\"https:\/\/medsbase.com\/ja\/hgh-191aa\/\">HGH 191AA<\/a> \u3092\u5168\u6d3b\u6027\u6bd4\u8f03\u5bfe\u7167\u3068\u3057\u3066<\/li>\n<li><strong>Lipogenic gene-expression studies<\/strong> \u2014 \u8102\u80aa\u7d30\u80de\u5206\u5316\u3001\u8102\u80aa\u6ef4\u5f62\u6210\u3001PPAR\u03b3\u304a\u3088\u3073SREBP-1\u7d4c\u8def\u306e\u76f8\u4e92\u4f5c\u7528<\/li>\n<li><strong>Visceral adiposity studies<\/strong> \u2014 \u3068\u306e\u76f4\u63a5\u6bd4\u8f03 <a href=\"https:\/\/medsbase.com\/ja\/tesamorelin\/\">Tesamorelin<\/a> as the GHRH-axis visceral-fat-reducing tool; published interest in dissecting GH-receptor-dependent vs GH-receptor-independent visceral-fat-loss mechanisms<\/li>\n<li><strong>Glucose homeostasis studies<\/strong> \u2014 unlike full-length HGH, HGH Fragment 176-191 does not produce the insulin-counter-regulatory effects observed with parent HGH; published studies uses this difference to dissect direct GH glycaemic effects<\/li>\n<li><strong>Comparative HGH-axis studies<\/strong> \u2014 \u30d9\u30f3\u30c1\u30de\u30fc\u30af\u6bd4\u8f03 <a href=\"https:\/\/medsbase.com\/ja\/hgh-191aa\/\">HGH 191AA<\/a> (\u5168\u9577\u89aaHGH), <a href=\"https:\/\/medsbase.com\/ja\/tesamorelin\/\">Tesamorelin<\/a> (\u5185\u81d3\u8102\u80aaGHRH\u30a2\u30ca\u30ed\u30b0)\u3001\u304a\u3088\u3073 <a href=\"https:\/\/medsbase.com\/ja\/sermorelin\/\">Sermorelin<\/a> \/ <a href=\"https:\/\/medsbase.com\/ja\/cjc-1295-with-dac\/\">CJC-1295<\/a> (GHRH\u8ef8\u523a\u6fc0\u5264).<\/li>\n<\/ul>\n<p>For broader context on where HGH Fragment 176-191 fits within the growth-axis and adipose-tissue studies landscape, see <a href=\"https:\/\/medsbase.com\/ja\/hgh-191aa\/\">HGH 191AA<\/a> \u5168\u9577\u89aa\u30da\u30d7\u30c1\u30c9\u3068\u3057\u3066\u3001, <a href=\"https:\/\/medsbase.com\/ja\/tesamorelin\/\">Tesamorelin<\/a> \u5185\u81d3\u8102\u80aa\u84c4\u7a4d\u306b\u5bfe\u3059\u308bGHRH\u8ef8\u30a2\u30d7\u30ed\u30fc\u30c1\u3001\u304a\u3088\u3073 <a href=\"https:\/\/medsbase.com\/ja\/sermorelin\/\">Sermorelin<\/a> + <a href=\"https:\/\/medsbase.com\/ja\/cjc-1295-with-dac\/\">CJC-1295 with DAC<\/a> for endogenous GH-pulse support. Browse the full <a href=\"https:\/\/medsbase.com\/ja\/peptides\/\">\u30da\u30d7\u30c1\u30c9\u30ab\u30bf\u30ed\u30b0<\/a> \u5316\u5408\u7269\u9078\u629e\u306e\u305f\u3081\u306b\u3002 <\/p>\n<h2>\u5229\u7528\u53ef\u80fd\u306a\u529b\u4fa1\u3068\u6fc3\u5ea6<\/h2>\n<p>MedsBase stocks HGH Fragment 176-191 in three lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30d0\u30a4\u30a2\u30eb\u529b\u4fa1<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u4ee3\u8868\u7684\u306a\u4f7f\u7528\u4f8b<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30d1\u30c3\u30af\u30b5\u30a4\u30ba<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Short protocols, pilot dosing, single-cohort lipolysis studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength, multi-week protocols<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>15\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u9577\u671f\u30b5\u30a4\u30af\u30eb\u306e\u30d7\u30ed\u30c8\u30b3\u30eb\u30011 mg\u3042\u305f\u308a\u306e\u6700\u4f4e\u30b3\u30b9\u30c8\u3001\u8907\u6570\u30b3\u30db\u30fc\u30c8\u7814\u7a76<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All three strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful when users want to minimise injection volume in rodent protocols. <\/p>\n<h2>\u6bd4\u8f03 \u2014 HGH Fragment 176-191 vs HGH 191AA<\/h2>\n<p>HGH Fragment 176-191 \u3068 <a href=\"https:\/\/medsbase.com\/ja\/hgh-191aa\/\">HGH 191AA<\/a> are a structure-function decoupled pair \u2014 the fragment is literally a piece of the full-length parent. Comparing them isolates the GH-receptor-binding activity (present in full-length, absent in fragment) from the lipolytic activity (present in both). The comparison is one of the cleanest mechanistic dissections available in current growth-axis studies. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u8a55\u4fa1\u9805\u76ee<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HGH\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8176-191<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HGH 191AA\uff08\u5168\u9577\uff09<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u30a2\u30df\u30ce\u9178\u6570<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">16\u30a2\u30df\u30ce\u9178\uff08\u7d041.8 kDa\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">191\u30a2\u30df\u30ce\u9178\uff08\u7d0422 kDa\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>GH\u53d7\u5bb9\u4f53\u7d50\u5408<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u306a\u3057\uff08\u7d50\u5408\u30c9\u30e1\u30a4\u30f3\u306fN\u672b\u7aef\u306b\u5b58\u5728\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u3042\u308a\uff08\u5168\u9577\u5206\u5b50\uff09<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>IGF-1\u8a98\u5c0e<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u306a\u3057<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u5b9f\u8cea\u7684\u306a\u809d\u8a98\u5c0e<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u8102\u80aa\u5206\u89e3\u6d3b\u6027<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Yes (preserved)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u306f\u3044\uff08\u5168\u9577\u89aa\u30da\u30d7\u30c1\u30c9\u6d3b\u6027\uff09<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u6210\u9577\u4fc3\u9032\u52b9\u679c<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u306a\u3057<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u5b9f\u8cea\u7684\uff08\u6a19\u6e96\u7684\u306a\u540c\u5316\u30da\u30d7\u30c1\u30c9\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u30a4\u30f3\u30b9\u30ea\u30f3\u62ee\u6297\u8abf\u7bc0\u4f5c\u7528<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u306a\u3057<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u306f\u3044\uff08\u4e00\u904e\u6027\u306e\u30a4\u30f3\u30b9\u30ea\u30f3\u62b5\u6297\u6027\uff09<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u8840\u6f3f\u4e2d\u534a\u6e1b\u671f<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u7d0430\u5206<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u7d043\uff5e5\u6642\u9593<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u627f\u8a8d\u81e8\u5e8a\u7528\u9014<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u306a\u3057<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u8907\u6570\u306e\u9069\u5fdc\u75c7\uff08Genotropin\u3001Humatrope\u306a\u3069\uff09<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u4e00\u822c\u7684\u306a\u7528\u91cf<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">200\uff5e500 mcg\u30011\u65e51\uff5e3\u56de<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1\u56de\u3042\u305f\u308a1\uff5e8 IU<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies interested in isolated lipolysis pharmacology without the confound of GH-receptor-driven growth and metabolic effects, HGH Fragment 176-191 is the canonical &#8220;lipolysis-only&#8221; tool. For studies investigating the full GH\/IGF axis or comparing with secretagogue-driven endogenous GH release, <a href=\"https:\/\/medsbase.com\/ja\/hgh-191aa\/\">HGH 191AA<\/a> is the appropriate full-length reference. Many published studies designs use both in parallel arms to dissect which HGH effects depend on GH-receptor signalling vs which arise from the C-terminal lipolytic mechanism. <\/p>\n<h2>\u4fdd\u7ba1\u65b9\u6cd5\u3068\u518d\u6eb6\u89e3<\/h2>\n<p><strong>\u518d\u6eb6\u89e3\u524d\uff1a<\/strong> \u77ed\u671f\u4f7f\u7528\u306e\u30ef\u30fc\u30ad\u30f3\u30b0\u30b9\u30c8\u30c3\u30af\u3068\u3057\u3066\u3001\u51cd\u7d50\u4e7e\u71e5\u30d0\u30a4\u30a2\u30eb\u306f\u5143\u306e\u5305\u88c5\u306e\u307e\u307e2\uff5e8 \u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u672a\u958b\u5c01\u306e\u9577\u671f\u4fdd\u5b58\u306e\u5834\u5408\u306f\u3001\u221220 \u00b0C\u3067\u51cd\u7d50\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u51cd\u7d50\u4e7e\u71e5HGH Fragment 176-191\u306f\u51b7\u8535\u3067\u6700\u592724\u304b\u6708\u3001\u221220 \u00b0C\u3067\u6700\u592736\u304b\u6708\u5b89\u5b9a\u3067\u3059\u3002\u51cd\u7d50\u4e7e\u71e5\u7c89\u672b\u306e\u51cd\u7d50\u878d\u89e3\u30b5\u30a4\u30af\u30eb\u306f\u907f\u3051\u3066\u304f\u3060\u3055\u3044\u3002\u4ed6\u306e\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u7d50\u5408\u30da\u30d7\u30c1\u30c9\u3068\u540c\u69d8\u306b\u3001\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8\u306e\u6d3b\u6027\u306f\u7121\u50b7\u306eCys182\u2013Cys189\uff08\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8\u756a\u53f7\u4ed8\u3051\u3067\u306fCys7\u2013Cys14\uff09\u7d50\u5408\u306b\u4f9d\u5b58\u3057\u307e\u3059 \u2014 \u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u7d50\u5408\u3092\u7834\u58ca\u3059\u308b\u53d6\u308a\u6271\u3044\u306f\u6d3b\u6027\u3092\u4f4e\u4e0b\u3055\u305b\u307e\u3059\u3002 <strong>\u518d\u6eb6\u89e3\u624b\u9806\uff1a<\/strong> \u30da\u30d7\u30c1\u30c9\u30d0\u30a4\u30a2\u30eb\u306e\u5074\u58c1\u306b\u6cbf\u3063\u3066\u9759\u83cc\u6c34\u3092\u6ce8\u5165\u3057\u3066\u304f\u3060\u3055\u3044\uff08\u51cd\u7d50\u4e7e\u71e5\u30b1\u30fc\u30ad\u306b\u76f4\u63a5\u304b\u3051\u306a\u3044\u3067\u304f\u3060\u3055\u3044\uff09\u30025 mg\u30d0\u30a4\u30a2\u30eb\u306e\u5834\u5408\u30012.0 mL\u306e\u9759\u83cc\u6c34\u30672.5 mg\/mL\u306e\u4f7f\u7528\u6fc3\u5ea6\u306b\u306a\u308a\u307e\u3059 \u2014 0.04 mL\u3067100 mcg\u30010.1 mL\u3067250 mcg\u30010.2 mL\u3067500 mcg\u3092\u6295\u4e0e\u3057\u307e\u3059\u3002\u9759\u304b\u306b\u65cb\u56de\u3055\u305b\u3066\u304f\u3060\u3055\u3044 \u2014 \u884c\u3046 <strong>\u3057\u307e\u305b\u3093<\/strong> \u632f\u3063\u3066\u2014 \u5b8c\u5168\u306b\u6eb6\u89e3\u3059\u308b\u307e\u30672\uff5e5\u5206\u9593\u9759\u7f6e\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u6b63\u3057\u304f\u518d\u69cb\u6210\u3055\u308c\u305f\u6eb6\u6db2\u306f\u900f\u660e\u3067\u7121\u8272\u3067\u306a\u3051\u308c\u3070\u306a\u308a\u307e\u305b\u3093\u3002 <strong>\u5b8c\u5168\u306b\u518d\u6eb6\u89e3\u3057\u305f\u6eb6\u6db2\u306f\u3001\u7121\u8272\u900f\u660e\u3067\u3042\u308b\u5fc5\u8981\u304c\u3042\u308a\u307e\u3059\u3002<\/strong> \u6700\u9069\u306a\u5b89\u5b9a\u6027\u306e\u305f\u3081\u30012\uff5e8 \u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3057\u300130\u65e5\u4ee5\u5185\u306b\u4f7f\u7528\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u518d\u69cb\u6210\u3057\u305f\u6eb6\u6db2\u306f\u51cd\u7d50\u3057\u306a\u3044\u3067\u304f\u3060\u3055\u3044 \u2014 \u51cd\u7d50\u878d\u89e3\u30b5\u30a4\u30af\u30eb\u306f\u30da\u30d7\u30c1\u30c9\u306e\u5b8c\u5168\u6027\u3092\u4f4e\u4e0b\u3055\u305b\u3001\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u7d50\u5408\u3092\u7834\u58ca\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u6fc1\u308a\u3001\u6c88\u6bbf\u3001\u307e\u305f\u306f\u5909\u8272\u304c\u898b\u3089\u308c\u308b\u30d0\u30a4\u30a2\u30eb\u306f\u5ec3\u68c4\u3057\u3066\u304f\u3060\u3055\u3044\u3002 <\/p>\n<h2 id=\"faqs\">\u3088\u304f\u3042\u308b\u8cea\u554f<\/h2>\n<h3>What is HGH Fragment 176-191 used for in studies?<\/h3>\n<p>HGH Fragment 176-191 is used in studies investigating isolated adipocyte lipolysis pharmacology, obesity and body-composition regulation without growth-axis confound, HGH structure-function dissection, lipogenic gene-expression regulation, regional adipose-tissue depot effects, and comparative GH-axis vs lipolysis-only studies designs. It is the canonical &#8220;lipolysis-only&#8221; peptide derived from native HGH. The pharmaceutical-grade HGH Fragment 176-191 sold here is <strong>\u3057\u307e\u305b\u3093<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>HGH Fragment 176-191\u306fHGH 191AA\u3068\u3069\u3046\u9055\u3044\u307e\u3059\u304b\uff1f<\/h3>\n<p>HGH Fragment 176-191\u306f\u308f\u305a\u304b16\u30a2\u30df\u30ce\u9178\u3067\u3042\u308a\u3001\u5168\u9577191\u30a2\u30df\u30ce\u9178\u306eHGH\u306eC\u672b\u7aef\u90e8\u5206\u3067\u3059\u3002\u3053\u306e\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8\u306fGH\u53d7\u5bb9\u4f53\u7d50\u5408\u30c9\u30e1\u30a4\u30f3\uff08\u89aa\u5206\u5b50\u306eN\u672b\u7aef\u90e8\u5206\u306b\u5b58\u5728\uff09\u3092\u6b20\u3044\u3066\u3044\u308b\u305f\u3081\u3001GHR\u306b\u7d50\u5408\u305b\u305a\u3001IGF-1\u3092\u8a98\u5c0e\u305b\u305a\u3001\u5b8c\u5168\u9577HGH\u306e\u6210\u9577\u4fc3\u9032\u4f5c\u7528\u3084\u30a4\u30f3\u30b9\u30ea\u30f3\u62ee\u6297\u8abf\u7bc0\u4f5c\u7528\u3092\u4e00\u5207\u751f\u3058\u307e\u305b\u3093\u3002\u8102\u80aa\u5206\u89e3\u4f5c\u7528\u3068\u6297\u8102\u80aa\u751f\u6210\u4f5c\u7528\u306e\u307f\u3092\u4fdd\u6301\u3057\u3066\u3044\u307e\u3059\u3002 <a href=\"https:\/\/medsbase.com\/ja\/hgh-191aa\/\">HGH 191AA<\/a> \u306f\u3001\u8102\u80aa\u5206\u89e3\u4f5c\u7528\u3068\u6210\u9577\u8ef8\u4f5c\u7528\u306e\u4e21\u65b9\u3092\u6301\u3064\u5b8c\u5168\u9577\u306e\u89aa\u5206\u5b50\u3067\u3059\u3002 <\/p>\n<h3>HGH Fragment 176-191\u306fAOD9604\u3068\u3069\u3046\u9055\u3044\u307e\u3059\u304b\uff1f<\/h3>\n<p>\u305d\u308c\u3089\u306f <strong>\u7570\u306a\u308b\u5316\u5408\u7269<\/strong> that are frequently confused. HGH Fragment 176-191 (CAS 66004-57-7) is the unmodified C-terminal fragment of native HGH. AOD9604 (CAS 221231-10-9) is a modified analog developed by Metabolic Pharmaceuticals \u2014 specifically, AOD9604 adds an N-terminal tyrosine substitution producing Tyr-HGH 177-191, with engineered changes to the disulfide bridge for improved stability and oral bioavailability studies. The two have related but distinct pharmacology. This product is the unmodified 176-191 fragment, not AOD9604. <\/p>\n<h3>What is the typical HGH Fragment 176-191 dose?<\/h3>\n<p>Published preclinical protocols typically use 200\u2013500\u00a0mcg per administration, given subcutaneously 1\u20133 times daily for 4\u201312 week cycles. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 0.04\u00a0mL equals 100\u00a0mcg, 0.2\u00a0mL equals 500\u00a0mcg. <\/p>\n<h3>HGH Fragment 176-191\u306fFDA\u627f\u8a8d\u3055\u308c\u3066\u3044\u307e\u3059\u304b\uff1f<\/h3>\n<p>No. HGH Fragment 176-191 is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. The related compound AOD9604 was investigated in clinical trials for obesity but did not achieve regulatory approval. <\/p>\n<h3>HGH Fragment 176-191\u306e\u4fdd\u7ba1\u65b9\u6cd5\u3092\u6559\u3048\u3066\u304f\u3060\u3055\u3044\u3002<\/h3>\n<p>\u51cd\u7d50\u4e7e\u71e5\u30d0\u30a4\u30a2\u30eb\uff1a\u77ed\u671f\u4f7f\u7528\u306e\u30ef\u30fc\u30ad\u30f3\u30b0\u30b9\u30c8\u30c3\u30af\u306f2\uff5e8\u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3001\u672a\u958b\u5c01\u30d0\u30a4\u30a2\u30eb\u306e\u9577\u671f\u4fdd\u5b58\u306f-20\u00b0C\u3067\u51b7\u51cd\u4fdd\u5b58\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u6eb6\u89e3\u5f8c\u6eb6\u6db2\uff1a2\uff5e8\u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3057\u300130\u65e5\u4ee5\u5185\u306b\u3054\u4f7f\u7528\u304f\u3060\u3055\u3044\u3002\u6eb6\u89e3\u5f8c\u6eb6\u6db2\u306f\u51cd\u7d50\u3057\u306a\u3044\u3067\u304f\u3060\u3055\u3044\u3002\u51cd\u7d50\u878d\u89e3\u30b5\u30a4\u30af\u30eb\u306f\u30da\u30d7\u30c1\u30c9\u3092\u5206\u89e3\u3057\u3001\u91cd\u8981\u306aCys182\u2013Cys189\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u7d50\u5408\u3092\u640d\u306a\u3046\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u5e38\u306b\u76f4\u5c04\u5149\u3092\u907f\u3051\u3066\u4fdd\u7ba1\u3057\u3066\u304f\u3060\u3055\u3044\u3002 <\/p>\n<h3>HGH Fragment 176-191\u306e\u6eb6\u89e3\u65b9\u6cd5\u3092\u6559\u3048\u3066\u304f\u3060\u3055\u3044\u3002<\/h3>\n<p>\u4e0a\u8a18\u306e\u518d\u6eb6\u89e3\u624b\u9806\u306b\u5f93\u3063\u3066\u304f\u3060\u3055\u3044\u3002\u6ce8\u5c04\u7528\u9759\u83cc\u6c34\u3092\u30d0\u30a4\u30a2\u30eb\u306e\u5185\u58c1\u306b\u6cbf\u3063\u3066\uff08\u51cd\u7d50\u4e7e\u71e5\u30b1\u30fc\u30ad\u306b\u76f4\u63a5\u5f53\u3066\u306a\u3044\u3088\u3046\u306b\uff09\u52a0\u3048\u3001\u9759\u304b\u306b\u65cb\u56de\u3055\u305b\u3001\u5b8c\u5168\u306b\u6eb6\u89e3\u3059\u308b\u307e\u30672\uff5e5\u5206\u9593\u7f6e\u304d\u307e\u3059\u3002 <strong>\u3057\u307e\u305b\u3093<\/strong> \u30d0\u30a4\u30a2\u30eb\u3092\u632f\u3089\u306a\u3044\u3067\u304f\u3060\u3055\u3044\u3002\u6fc0\u3057\u3044\u64b9\u62cc\u306f\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u7d50\u5408\u3092\u7834\u58ca\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u6b63\u3057\u304f\u6eb6\u89e3\u3055\u308c\u305f\u6eb6\u6db2\u306f\u7121\u8272\u900f\u660e\u3067\u3059\u30025 mg\u30d0\u30a4\u30a2\u30eb\u306b2.0 mL\u306e\u6eb6\u89e3\u6db2\u3092\u4f7f\u7528\u3057\u305f\u5834\u5408\u3001\u4f5c\u696d\u6fc3\u5ea6\u306f2.5 mg\/mL\u3068\u306a\u308a\u307e\u3059\u3002 <\/p>\n<h3>MedsBase\u3067\u306f\u3069\u306e\u5bb9\u91cf\u306e\u30ec\u30bf\u30eb\u30c8\u30eb\u30c1\u30c9\u3092\u53d6\u308a\u63c3\u3048\u3066\u3044\u307e\u3059\u304b\uff1f<\/h3>\n<p>MedsBase carries HGH Fragment 176-191 in 5\u00a0mg, 10\u00a0mg, and 15\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>HGH Fragment 176-191\u304cIGF-1\u306b\u5f71\u97ff\u3092\u4e0e\u3048\u306a\u3044\u306e\u306f\u306a\u305c\u3067\u3059\u304b\uff1f<\/h3>\n<p>The GH-receptor-binding surface of native human growth hormone is located in the N-terminal portion of the 191-amino-acid molecule, not in the C-terminal 176\u2013191 region. Because the fragment lacks the receptor-binding domain, it cannot activate the GH receptor; without GHR activation, the downstream JAK2\/STAT5 signalling cascade that drives hepatic IGF-1 transcription is not engaged. This structural-functional decoupling is the principal scientific reason the fragment retains studies interest as a lipolysis-isolating tool. <\/p>\n<h3>GH\u53d7\u5bb9\u4f53\u7d50\u5408\u306b\u3088\u308b\u3082\u306e\u3067\u306f\u306a\u3044\u5834\u5408\u3001\u8102\u80aa\u5206\u89e3\u6d3b\u6027\u306f\u3069\u3053\u304b\u3089\u751f\u3058\u308b\u306e\u3067\u3059\u304b\uff1f<\/h3>\n<p>The exact molecular target of HGH Fragment 176-191&#8217;s lipolytic action remains an active studies question. Proposed mechanisms include direct interaction with adipocyte beta-3 adrenergic receptors, modulation of hormone-sensitive lipase activity, and altered fatty-acid oxidation kinetics in adipose tissue. The fragment also suppresses lipogenic gene expression, suggesting it acts on multiple adipocyte-specific pathways simultaneously. Published studies continues to characterise the exact receptor or binding-site target. <\/p>\n<h3>Does HGH Fragment 176-191 cause side reported effects?<\/h3>\n<p>Published preclinical studies has documented a notably clean safety profile at typical doses, with the main on-target effect being lipolysis. The absence of GH-receptor binding means none of the GH-axis side effects observed with full-length HGH (transient insulin resistance, joint discomfort, sodium retention, mitogenic signalling) are present. Long-term human safety data is limited because the unmodified fragment has not undergone modern regulatory review (though the related AOD9604 has been investigated more extensively in clinical trials). <\/p>\n<h3>HGH\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8176-191\u306e\u534a\u6e1b\u671f\u306f\u3069\u308c\u304f\u3089\u3044\u3067\u3059\u304b\uff1f<\/h3>\n<p>In preclinical studies, HGH Fragment 176-191 has a plasma half-life of approximately 30 minutes following subcutaneous administration \u2014 shorter than full-length HGH (~3\u20135 hours) due to the smaller molecular size and absence of albumin-binding modifications. The short half-life means typical protocols use multiple daily administrations or continuous-release formulations for sustained-exposure work. <\/p>\n<h3>How long does HGH Fragment 176-191 take to show effects in preclinical studies?<\/h3>\n<p>Acute effects on adipocyte lipolysis and fatty-acid mobilisation are detectable within hours of administration. Body-composition effects in DIO rodent models typically become statistically significant after 2\u20134 weeks of regular dosing and continue to accrue through 8\u201312 weeks of continuous administration. The kinetics are similar to other adipose-tissue-targeted compounds. <\/p>\n<h3>HGH\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8176-191\u3092\u56fd\u969b\u914d\u9001\u3067\u6ce8\u6587\u3067\u304d\u307e\u3059\u304b\uff1f<\/h3>\n<p>\u306f\u3044\u3002MedsBase\u306f\u5c02\u7528\u306e\u30da\u30d7\u30c1\u30c9\u767a\u9001\u30cd\u30c3\u30c8\u30ef\u30fc\u30af\u3092\u901a\u3058\u3066\u3001HGH Fragment 176-191\u3092\u5168\u4e16\u754c\u3078\u304a\u5c4a\u3051\u3057\u3066\u3044\u307e\u3059\u3002\u30da\u30d7\u30c1\u30c9\u306e\u307f\u306e\u3054\u6ce8\u6587\u306f\u3001\u5f53\u793e\u306e\u72ec\u7acb\u3057\u305f\u30da\u30d7\u30c1\u30c9\u767a\u9001\u30b5\u30fc\u30d3\u30b9\u306e\u5bfe\u8c61\u3068\u306a\u308a\u307e\u3059\u3002\u3059\u3079\u3066\u306e\u3054\u6ce8\u6587\u306f\u3001\u6e29\u5ea6\u7ba1\u7406\u3055\u308c\u305f\u68b1\u5305\u3067\u5b8c\u5168\u306a\u8ffd\u8de1\u4ed8\u304d\u3067\u767a\u9001\u3055\u308c\u3001\u5f0a\u793e\u306e <a href=\"https:\/\/medsbase.com\/ja\/medsbase-re-shipment-assurance-policy\/\">\u518d\u767a\u9001\u4fdd\u8a3c\u30dd\u30ea\u30b7\u30fc<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Adipose, Growth-Axis, and Body-Composition Studies<\/h2>\n<ul>\n<li><a href=\"\/ja\/hgh-191aa\/\"><strong>HGH 191AA<\/strong><\/a> \u2014 \u5168\u9577\u7d44\u63db\u3048\u30d2\u30c8\u6210\u9577\u30db\u30eb\u30e2\u30f3 \u2014 \u3053\u306e\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8\u306e\u89aa\u5206\u5b50<\/li>\n<li><a href=\"\/ja\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 GHRH analog \u2014 visceral adipose-tissue studies; FDA-approved for HIV-associated lipodystrophy<\/li>\n<li><a href=\"\/ja\/cjc-1295-with-dac\/\"><strong>CJC-1295 with DAC<\/strong><\/a> \u2014 Long-acting GHRH analog \u2014 endogenous GH-pulse support<\/li>\n<li><a href=\"\/ja\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 GHRH(1-29) analog \u2014 short-acting GHRH use<\/li>\n<li><a href=\"\/ja\/ipamorelin\/\"><strong>Ipamorelin<\/strong><\/a> \u2014 Selective growth hormone secretagogue \u2014 clean GH pulse studies<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>\u53c2\u8003\u6587\u732e<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore the HGH-axis studies landscape<\/strong><\/p>\n<p style=\"margin: 0;\">\u3059\u3079\u3066\u3092\u95b2\u89a7 <a href=\"https:\/\/medsbase.com\/ja\/peptides\/\"><strong>\u30da\u30d7\u30c1\u30c9\u30ab\u30bf\u30ed\u30b0<\/strong><\/a>, \u3001\u95a2\u9023\u3059\u308b\u6210\u9577\u8ef8\u5316\u5408\u7269\u3068\u3057\u3066 <a href=\"https:\/\/medsbase.com\/ja\/hgh-191aa\/\">HGH 191AA<\/a> (\u5168\u9577\u89aaHGH), <a href=\"https:\/\/medsbase.com\/ja\/tesamorelin\/\">Tesamorelin<\/a> \uff08\u5185\u81d3\u8102\u80aa\u578bGHRH\u30a2\u30ca\u30ed\u30b0\uff09\u3001, <a href=\"https:\/\/medsbase.com\/ja\/sermorelin\/\">Sermorelin<\/a> KYC\uff08Know Your Customer\uff09 <a href=\"https:\/\/medsbase.com\/ja\/cjc-1295-with-dac\/\">CJC-1295 with DAC<\/a> for endogenous-pulse studies.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 \u30d2\u30c8\u6210\u9577\u30db\u30eb\u30e2\u30f3\u306e16\u30a2\u30df\u30ce\u9178C\u672b\u7aef\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8<br \/>\n\u2705 \u8102\u80aa\u5206\u89e3\u6d3b\u6027\u3092\u4fdd\u6301\u3001GH\u53d7\u5bb9\u4f53\u7d50\u5408\u306a\u3057<br \/>\n\u2705 IGF-1\u8a98\u5c0e\u30fb\u6210\u9577\u4fc3\u9032\u52b9\u679c\u306a\u3057<br \/>\n\u2705 Lipolysis-only tool (distinct from AOD9604)<br \/>\n\u2705 HPLC\u7d14\u5ea699%\u4ee5\u4e0a\u3001\u5206\u6790\u8a3c\u660e\u66f8\u306f\u3054\u8981\u671b\u306b\u5fdc\u3058\u3066<\/p>\n<p><strong>HGH\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8176-191<\/strong> \u5408\u6210\u30da\u30d7\u30c1\u30c9\u5316\u5408\u7269\u3092\u542b\u307f\u307e\u3059\u3002<\/p>","protected":false},"featured_media":70959,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6288,6289,5441],"class_list":["post-70781","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-hgh","product_tag-hgh-fragment","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product\/70781","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/comments?post=70781"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media\/70959"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media?parent=70781"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_brand?post=70781"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_cat?post=70781"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_tag?post=70781"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}